Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Publications

2024

  • Turkowski K, Herzberg F, Günther S, Weigert A, Haselbauer T, Fink L, Brunn D, Grimminger F, Seeger W, Sültmann H, Stiewe T, Pullamsetti SS, Savai R. miR-147b mediated suppression of DUSP8 promotes lung cancer progression. Oncogene, doi: 10.1038/s41388-024-02969-7, 2024
  • Driedonks TAP, Nyberg LH, Conte A, Ma Z, Pekosz A, Duban E, Tonevitsky A, Sültmann H, Turchinovich A, Witwer KW. Viral and host small RNA transcriptome analysis of SARS-CoV-1 and SARS-CoV-2-infected human cells reveals novel viral short RNAs. Heliyon 10(3):e24570, 2024
  • Damiescu R, Yücer R, Klauck SM, Bringmann G, Efferth T, Dawood M. Jozimine A2, a dimeric naphthylisoquinoline (NIQ) alkaloid, shows in vitro cytotoxic effects against leukemia cells through NF-κB inhibition. Int J Mol Sci 25:3087, 2024.
  • Yücer R, Fayez S, Feineis D, Klauck SM, Shan L, Bringmann G, Efferth T, Dawood M. Cytotoxicity of dioncophylline A and related naphthylisoquinolines in leukemia cells, mediated by NF-kappaB inhibition, angiogenesis suppression, G2/M cell cycle arrest, and autophagy induction. Phytomedicine 126:155267, 2024

2023

  • Angeles AK, Janke F, Daum AK, Reck M, Schneider MA, Thomas M, Christopoulos P, Sültmann H. Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma. Br J Cancer 129(1):112-121, 2023
  • Görtz M, Baumgärtner K, Schmid T, Muschko M, Woessner P, Gerlach A, Byczkowski M, Sültmann H, Duensing S, Hohenfellner M. An artificial intelligence-based chatbot for prostate cancer education: Design and patient evaluation study. Digit Health 9:20552076231173304, 2023
  • Scherr AL, Nader L, Xu K, Elssner C, Ridder DA, Nichetti F, Mastel M, Fritzsche S, Kelmendi E, Schmitt N, Hoffmeister-Wittmann P, Weiler SME, Korell F, Albrecht T, Schwab M, Isele H, Kessler A, Hüllein J, Seretny A, Ye L, Urbanik T, Welte S, Leblond AL, Heilig CE, Rahbari M, Ali A, Gallage S, Lenoir B, Wilhelm N, Gärtner U, Ogrodnik SJ, Springfeld C, Tschaharganeh D, Fröhling S, Longerich T, Schulze-Bergkamen H, Jäger D, Brandl L, Schirmacher P, Straub BK, Weber A, De Toni EN, Goeppert B, Heikenwälder M, Jackstadt R, Roessler S, Breuhahn K, Köhler BC. Etiology-independent activation of the LTß-LTßR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma. Hepatology, doi: 10.1097/HEP.0000000000000657, 2023
  • Zhou M, Boulos JC, Klauck SM, Efferth T. The cardiac glycoside ZINC253504760 induces parthanatos-type cell death and G2/M arrest via downregulation of MEK1/2 phosphorylation in leukemia cells. Cell Biol Toxicol 39(6):2971-2997, 2023
  • Boulos JC, Omer EA, Rigano D, Formisano C, Chatterjee M, Leich E, Klauck SM, Shan LT, Efferth T. Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma. Acta Pharmacol Sin 44(11):2265-2281, 2023
  • Zhou M, Boulos JC, Omer EA, Klauck SM, Efferth T. Modes of action of a novel c-MYC inhibiting 1,2,4-oxadiazole derivative in leukemia and breast cancer cells. Molecules 28(15):5658, 2023
  • Elbadawi M, Boulos JC, Dawood M, Zhou M, Gul W, ElSohly MA, Klauck SM, Efferth T. The novel Artemisinin dimer Isoniazide ELI-XXIII-98-2 induces c-MYC inhibition, DNA damage, and autophagy in leukemia cells. Pharmaceutics 15(4):1107, 2023

2022

  • Janke F, Angeles AK, Riediger AL, Bauer S, Reck M, Stenzinger A, Schneider MA, Muley T, Thomas M, Christopoulos P, Sültmann H. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients. Clin Epigenetics 14(1):163, 2022
  • Eickelschulte S, Riediger AL, Angeles AK, Janke F, Duensing S, Sültmann H, Görtz M. Biomarkers for the detection and risk stratification of aggressive prostate cancer. Cancers (Basel) 14(24):6094, 2022
  • Schindler H, Lusky F, Daniello L, Elshiaty M, Gaissmaier L, Benesova K, Souto-Carneiro M, Angeles AK, Janke F, Eichhorn F, Kazdal D, Schneider M, Liersch S, Klemm S, Schnitzler P, Stenzinger A, Sültmann H, Thomas M, Christopoulos P. Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors. Front Oncol 12:1010660, 2022
  • Wiedemann C, Kazdal D, Cvetkovic J, Kunz J, Fisch D, Kirchner M, Kriegsmann M, Sültmann H, Heussel CP, Bischoff H, Thomas M, Stenzinger A, Christopoulos P. Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report. Cold Spring Harb Mol Case Stud 8(6):a006234, 2022
  • Mack M, Broche J, George S, Hajjari Z, Janke F, Ranganathan L, Ashouri M, Bleul S, Desuki A, Engels C, Fliedner SMJ, Hartmann N, Hummel M, Janning M, Kiel A, Köhler T, Koschade S, Lablans M, Lambarki M, Loges S, Lueong S, Meyer S, Ossowski S, Scherer F, Schroeder C, Skowronek P, Thiede C, Uhl B, Vehreschild JJ, von Bubnoff N, Wagner S, Werner TV, Westphalen CB, Fresser P, Sültmann H, Tinhofer I, Winter C. The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients. J Lab Med 46(4):321-330, 2022
  • Görtz M, Nyarangi-Dix JN, Pursche L, Schütz V, Reimold P, Schwab C, Stenzinger A, Sültmann H, Duensing S, Schlemmer HP, Bonekamp D, Hohenfellner M, Radtke JP. Impact of surgeon's experience in rigid versus elastic MRI/TRUS-fusion biopsy to detect significant prostate cancer using targeted and systematic cores. Cancers (Basel) 14(4):886, 2022
  • Heitzer E, van den Broek D, Denis MG, Hofman P, Hubank M, Mouliere F, Paz-Ares L, Schuuring E, Sültmann H, Vainer G, Verstraaten E, de Visser L, Cortinovis D. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. ESMO Open 7(2):100399, 2022
  • Nientiedt C, Budczies J, Endris V, Kirchner M, Schwab C, Jurcic C, Behnisch R, Hoveida S, Lantwin P, Kaczorowski A, Geisler C, Dieffenbacher S, Falkenbach F, Franke D, Görtz M, Heller M, Himmelsbach R, Pecqueux C, Rath M, Reimold P, Schütz V, Simunovic I, Walter E, Hofer L, Gasch C, Schönberg G, Pursche L, Hatiboglu G, Nyarangi-Dix J, Sültmann H, Zschäbitz S, Koerber SA, Jäger D, Debus J, Duensing A, Schirmacher P, Hohenfellner M, Stenzinger A, Duensing S. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urol Oncol 40(1):8.e11-8.e18, 2022
  • Elbadawi M, Ammar RM, Rabini S, Klauck SM, Efferth T. Modulation of intestinal corticotropin-releasing hormone signaling by the herbal preparation STW 5-II: Possible mechanisms for irritable bowel syndrome management. Pharmaceuticals (Basel) 15(9):1121, 2022
  • Saeed MEM, Boulos JC, Mücklich SB, Leich E, Chatterjee M, Klauck SM, Efferth T. Disruption of lipid raft microdomains, regulation of CD38, TP53, and MYC signaling, and induction of apoptosis by Lomitapide in multiple myeloma cells. Cancer Genomics Proteomics 19(5):540-555, 2022.
  • Lu X, Blatt S, Dawood M, Klauck SM, Fleischer E, Kämmerer PW, Efferth T. Novel artemisinin derivative FO8643 with anti-angiogenic activity inhibits growth and migration of cancer cells via VEGFR2 signaling. Eur J Pharmacol 930:175158, 2022
  • Abdelfatah S, Naß J, Knorz C, Klauck SM, Küpper JH, Efferth T. Pyrrolizidine alkaloids cause cell cycle and DNA damage repair defects as analyzed by transcriptomics in cytochrome P450 3A4-overexpressing HepG2 clone 9 cells. Cell Biol Toxicol 38(2):325-345, 2022

2021

  • Angeles AK, Christopoulos P, Yuan Z, Bauer S, Janke F, Ogrodnik SJ, Reck M, Schlesner M, Meister M, Schneider MA, Dietz S, Stenzinger A, Thomas M, Sültmann H. Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. NPJ Precis Oncol 5(1):100, 2021
  • Angeles AK, Janke F, Bauer S, Christopoulos P, Riediger AL, Sültmann H. Liquid biopsies beyond mutation calling: Genomic and epigenomic features of cell-free DNA in cancer. Cancers (Basel) 13(22):5615, 2021
  • Christopoulos P, Dietz S, Angeles AK, Rheinheimer S, Kazdal D, Volckmar AL, Janke F, Endris V, Meister M, Kriegsmann M, Zemojtel T, Reck M, Stenzinger A, Thomas M, Sültmann H. Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies. Transl Lung Cancer Res 10(5):2118-2131, 2021
  • Bauer S, Ratz L, Heckmann-Nötzel D, Kaczorowski A, Hohenfellner M, Kristiansen G, Duensing S, Altevogt P, Klauck SM, Sültmann H. miRNA-449a repression leads to enhanced NOTCH signaling in TMPRSS2:ERG fusion positive prostate cancer cells. Cancers (Basel) 13(5):964, 2021
  • Tolkach Y, Zarbl R, Bauer S, Ritter M, Ellinger J, Hauser S, Hüser L, Klauck SM, Altevogt P, Sültmann H, Dietrich D, Kristiansen G. DNA promoter methylation and ERG regulate the expression of CD24 in prostate cancer. Am J Pathol 191(4):618-630, 2021
  • Elsayed M, Bozorgmehr F, Kazdal D, Volckmar AL, Sültmann H, Fischer JR, Kriegsmann M, Stenzinger A, Thomas M, Christopoulos P. Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancer. Front Oncol 11:670483, 2021
  • Schmitz D, Kazdal D, Allgäuer M, Trunk M, Vornhusen S, Nahm AM, Doll M, Weingärtner S, Endris V, Penzel R, Kirchner M, Brandt R, Neumann O, Sültmann H, Budczies J, Kienle P, Magdeburg R, Hetjens S, Schirmacher P, Bergmann F, Rudi J, Stenzinger A, Volckmar AL. KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas. Genes Chromosomes Cancer 60(7):489-497, 2021
  • Lu X, Yan G, Dawood M, Klauck SM, Sugimoto Y, Klinger A, Fleischer E, Shan L, Efferth T. A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells. Biochem Pharmacol 194:114677, 2021
  • Boulos JC, Saeed MEM, Chatterjee M, Bülbül Y, Crudo F, Marko D, Munder M, Klauck SM, Efferth T. Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells. Pharmaceuticals (Basel) 14(11):1126, 2021
  • Lu X, Yan G, Klauck SM, Fleischer E, Klinger A, Sugimoto Y, Shan L, Efferth T. Cytotoxicity of 4-hydroxy-N-(naphthalen-1-yl)-2-oxo-2H-chromene-3-carboxamide in multidrug-resistant cancer cells through activation of PERK/eIF2alpha/ATF4 pathway. Biochem Pharmacol 193:114788, 2021
  • Kadioglu O, Klauck SM, Fleischer E, Shan L, Efferth T. Selection of safe artemisinin derivatives using a machine learning-based cardiotoxicity platform and in vitro and in vivo validation. Arch Toxicol 95(7):2485-2495, 2021
  • Elbadawi M, Ammar RM, Aziz-Kalbhenn H, Rabini S, Klauck SM, Dawood M, Saeed M, Kampf CJ, Efferth T. Anti-inflammatory and tight junction protective activity of the herbal preparation STW 5-II on mouse intestinal organoids. Phytomedicine 88:153589, 2021
  • Hegazy MF, Dawood M, Mahmoud N, Elbadawi M, Sugimoto Y, Klauck SM, Mohamed N, Efferth T. 2alpha-Hydroxyalantolactone from Pulicaria undulata: activity against multidrug-resistant tumor cells and modes of action. Phytomedicine 81:153409, 2021

2020

  • Dietz S, Christopoulos P, Yuan Z, Angeles AK, Gu L, Volckmar AL, Ogrodnik SJ, Janke F, Dalle Fratte C, Zemojtel T, Schneider MA, Kazdal D, Endris V, Meister M, Muley T, Cecchin E, Reck M, Schlesner M, Thomas M, Stenzinger A, Sültmann H. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. EBioMedicine 62:103103, 2020
  • Angeles AK, Heckmann D, Flosdorf N, Duensing S, Sültmann H. The ERG-regulated LINC00920 promotes prostate cancer cell survival via the 14-3-3ε-FOXO pathway. Mol Cancer Res 18(10):1545-1559, 2020
  • Janke F, Bozorgmehr F, Wrenger S, Dietz S, Heussel CP, Heussel G, Silva CF, Rheinheimer S, Feisst M, Thomas M, Golpon H, Günther A, Sültmann H, Muley T, Janciauskiene S, Meister M, Schneider MA. Novel liquid biomarker panels for a very early response capturing of NSCLC therapies in advanced stages. Cancers (Basel) 12(4):954, 2020
  • Müller S, Janke F, Dietz S, Sültmann H. Circulating microRNAs as potential biomarkers for lung cancer. Recent Results Cancer Res 215:299-318, 2020
  • Zapatka M, Borozan I, Brewer DS, Iskar M, Grundhoff A, Alawi M, Desai N, Sültmann H, Moch H, PCAWG Pathogens, Cooper CS, Eils R, Ferretti V, Lichter P, PCAWG Consortium. The landscape of viral associations in human cancers. Nat Genet 52(3):320-330, 2020; Author Correction: 55(6):1077, 2023
  • The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578(7793):82-93, 2020; Author Correction: 614(7948):E39, 2023
  • Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN, Islam SMA, Lopez-Bigas N, Klimczak LJ, McPherson JR, Morganella S, Sabarinathan R, Wheeler DA, Mustonen V, PCAWG Mutational Signatures Working Group, Getz G, Rozen SG, Stratton MR, PCAWG Consortium. The repertoire of mutational signatures in human cancer. Nature 578(7793):94-101, 2020; Author Correction: 614(7948):E41, 2023
  • Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowetz F, Mustonen V, Yuan K, Wang W, Morris QD, PCAWG Evolution & Heterogeneity Working Group, Spellman PT, Wedge DC, Van Loo P, PCAWG Consortium. The evolutionary history of 2,658 cancers. Nature 578(7793):122-128, 2020; Author Correction: 614(7948):E42, 2023
  • PCAWG Transcriptome Core Group, Calabrese C, Davidson NR, Demircioglu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H, PCAWG Transcriptome Working Group, Brazma A, Brooks AN, Göke J, Rätsch G, Schwarz RF, Stegle O, Zhang Z, PCAWG Consortium. Genomic basis for RNA alterations in cancer. Nature 578(7793):129-136, 2020; Author Correction: 614(7948):E37, 2023
  • Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, Khurana E, Waszak S, Korbel JO, Haber JE, Imielinski M, PCAWG Structural Variation Group, Weischenfeldt J, Beroukhim R, Campbell PJ, PCAWG Consortium. Patterns of somatic structural variation in human cancer genomes. Nature 578(7793):112-121, 2020; Author Correction: 614(7948):E38, 2023
  • Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, Hornshoj H, Hess JM, Juul RI, Lin Z, Feuerbach L, Sabarinathan R, Madsen T, Kim J, Mularoni L, Shuai S, Lanzós A, Herrmann C, Maruvka YE, Shen C, Amin SB, Bandopadhayay P, Bertl J, Boroevich KA, Busanovich J, Carlevaro-Fita J, Chakravarty D, Chan CWY, Craft D, Dhingra P, Diamanti K, Fonseca NA, Gonzalez-Perez A, Guo Q, Hamilton MP, Haradhvala NJ, Hong C, Isaev K, Johnson TA, Juul M, Kahles A, Kahraman A, Kim Y, Komorowski J, Kumar K, Kumar S, Lee D, Lehmann KV, Li Y, Liu EM, Lochovsky L, Park K, Pich O, Roberts ND, Saksena G, Schumacher SE, Sidiropoulos N, Sieverling L, Sinnott-Armstrong N, Stewart C, Tamborero D, Tubio JMC, Umer HM, Uusküla-Reimand L, Wadelius C, Wadi L, Yao X, Zhang CZ, Zhang J, Haber JE, Hobolth A, Imielinski M, Kellis M, Lawrence MS, von Mering C, Nakagawa H, Raphael BJ, Rubin MA, Sander C, Stein LD, Stuart JM, Tsunoda T, Wheeler DA, Johnson R, Reimand J, Gerstein M, Khurana E, Campbell PJ, López-Bigas N, PCAWG Drivers and Functional Interpretation Working Group, PCAWG Structural Variation Working Group, Weischenfeldt J, Beroukhim R, Martincorena I, Pedersen JS, Getz G, PCAWG Consortium. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature 578(7793):102-111, 2020; Author Correction: 614(7948):E40, 2023
  • Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Kelso S, MC3 Working Group, PCAWG novel somatic mutation calling methods working group, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L, PCAWG Consortium. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun 11(1):4748, 2020; Author Correction: 11(1):6232, 2020
  • Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, PCAWG Tumour Subtypes and Clinical Translation, Boutros PC, PCAWG Consortium. Sex differences in oncogenic mutational processes. Nat Commun 11(1):4330, 2020
  • Bhandari V, Li CH, Bristow RG, Boutros PC, PCAWG Consortium. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun 11(1):737, 2020; Author Correction: 13(1):7569, 2022
  • Carlevaro-Fita J, Lanzos A, Feuerbach L, Hong C, Mas-Ponte D, Pedersen JS, PCAWG Drivers and Functional Interpretation Group, Johnson R, PCAWG Consortium. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol 3(1):56, 2020; Author Correction: 5(1):1347, 2022
  • Cmero M, Yuan K, Ong CS, Schröder J, PCAWG Evolution and Heterogeneity Working Group, Corcoran NM, Papenfuss T, Hovens CM, Markowetz F, Macintyre G, PCAWG Consortium. Inferring structural variant cancer cell fraction. Nat Commun 11(1):730, 2020; Author Correction: 13(1):7568, 2022
  • Jiao W, Atwal G, Polak P, Karlic R, Cuppen E, PCAWG Tumor Subtypes and Clinical Translation Working Group, Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N, Getz G, Morris QD, Stein LD, PCAWG Consortium. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun 11(1):728, 2020; Author Correction: 13(1):7573, 2022
  • Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC, PCAWG Drivers and Functional Interpretation Working Group, Reimand J, PCAWG Consortium. Integrative pathway enrichment analysis of multivariate omics data. Nat Commun 11(1):735, 2020; Author Correction: 13(1):7570, 2022
  • Reyna MA, Haan D, Paczkowska M, Verbeke LPC, Vazquez M, Kahraman A, Pulido-Tamayo S, Barenboim J, Wadi L, Dhingra P, Shrestha R, Getz G, Lawrence MS, Pedersen JS, Rubin MA, Wheeler DA, Brunak S, Izarzugaza JMG, Khurana E, Marchal K, von Mering C, Sahinalp SC, Valencia A, PCAWG Drivers and Functional Interpretation Working Group, Reimand J, Stuart JM, Raphael BJ, PCAWG Consortium. Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun 11(1):729, 2020; Author Correction: 13(1):7566, 2022
  • Rubanova Y, Shi R, Harrigan CF, Li R, Wintersinger J, Sahin N, Deshwar AG, PCAWG Evolution and Heterogeneity Working Group, Morris QD, PCAWG Consortium. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun 11(1):731, 2020; Author Correction: 13(1):7567, 2022
  • Shuai S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger S, Stein LD, PCAWG Consortium. Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun 11(1):734, 2020; Author Correction: 13(1):7571, 2022
  • Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, Braun DM, Cortes-Ciriano I, Xi R, Kabbe R, Park PJ, Eils R, Schlesner M, PCAWG-Structural Variation Working Group, Brors B, Rippe K, Jones DTW, Feuerbach L, PCAWG Consortium. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun 11(1):733, 2020; Author Correction: 13(1):7574, 2022
  • Zhang Y, Chen F, Fonseca NA, He Y, Fujita M, Nakagawa H, Zhang Z, Brazma A, PCAWG Transcriptome Working Group, PCAWG Structural Variation Working Group, Creighton CJ, PCAWG Consortium. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun 11(1):736, 2020; Author Correction: 13(1):7572, 2022
  • Yakneen S, Waszak SM, PCAWG Technical Working Group, Gertz M, Korbel JO, PCAWG Consortium. Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol 38(3):288-292, 2020; Author Correction: 41(4):577, 2023
  • Rodriguez-Martin B, Alvarez EG, Baez-Ortega A, Zamora J, Supek F, Demeulemeester J, Santamarina M, Ju YS, Temes J, Garcia-Souto D, Detering H, Li Y, Rodriguez-Castro J, Dueso-Barroso A, Bruzos AL, Dentro SC, Blanco MG, Contino G, Ardeljan D, Tojo M, Roberts ND, Zumalave S, Edwards PA, Weischenfeldt J, Puiggròs M, Chong Z, Chen K, Lee EA, Wala JA, Raine KM, Butler A, Waszak SM, Navarro FCP, Schumacher SE, Monlong J, Maura F, Bolli N, Bourque G, Gerstein M, Park PJ, Wedge DC, Beroukhim R, Torrents D, Korbel JO, Martincorena I, Fitzgerald RC, Van Loo P, Kazazian HH, Burns KH, PCAWG Structural Variation Working Group, Campbell PJ, Tubio JMC, PCAWG Consortium. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet 52(3):306-319, 2020; Author Correction: 55(6):1080, 2023
  • Akdemir KC, Le VT, Chandran S, Li Y, Verhaak RG, Beroukhim R, Campbell PJ, Chin L, Dixon JR, Futreal PA, PCAWG Structural Variation Working Group, PCAWG Consortium. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet 52(3):294-305, 2020; Author Correction: 55(6):1079, 2023
  • Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS, PCAWG Structural Variation Working Group, Park PJ, PCAWG Consortium. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet 52(3):331-341, 2020; Author Correction: 55(6):1076, 2023
  • Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, Xu Y, Han L, Kim HL, Nakagawa H, Park K, Campbell PJ, Liang H, PCAWG Consortium. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet 52(3):342-352, 2020; Author Correction: 55(6):1078, 2023
  • Kaczorowski A, Tolstov Y, Falkenstein M, Vasioukhin V, Prigge ES, Geisler C, Kippenberger M, Nientiedt C, Ratz L, Kuryshev V, Herpel E, Kristiansen G, Sültmann H, Stenzinger A, Doeberitz MVK, Hohenfellner M, Duensing A, Duensing S. Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53. Urol Oncol 38(9):736 e731-736 e710, 2020
  • Kim-Wanner SZ, Assenov Y, Nair MB, Weichenhan D, Benner A, Becker N, Landwehr K, Kuner R, Sültmann H, Esteller M, Koch I, Lindner M, Meister M, Thomas M, Bieg M, Klingmueller U, Schlesner M, Warth A, Brors B, Seifried E, Bonig H, Plass C, Risch A, Muley T. Genome-wide DNA methylation profiling in early stage I lung adenocarcinoma reveals predictive aberrant methylation in the promoter region of the long non-coding RNA PLUT - an exploratory study. J Thorac Oncol 15(8):1338-1350, 2020
  • Nientiedt C, Endris V, Jenzer M, Mansour J, Sedehi NTP, Pecqueux C, Volckmar AL, Leichsenring J, Neumann O, Kirchner M, Hoveida S, Lantwin P, Kaltenecker K, Dieffenbacher S, Gasch C, Hofer L, Franke D, Tosev G, Görtz M, Schütz V, Radtke JP, Nyarangi-Dix J, Hatiboglu G, Simpfendörfer T, Schönberg G, Isaac S, Teber D, Koerber SA, Christofi G, Czink E, Kreuter R, Apostolidis L, Kratochwil C, Giesel F, Haberkorn U, Debus J, Sültmann H, Zschäbitz S, Jäger D, Duensing A, Schirmacher P, Grüllich C, Hohenfellner M, Stenzinger A, Duensing S. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naive metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel. Urol Oncol 38(7):637 e617-637 e627, 2020
  • Yan G, Dawood M, Böckers M, Klauck SM, Fottner C, Weber MM, Efferth T. Multiple modes of cell death in neuroendocrine tumors induced by artesunate. Phytomedicine 79:153332, 2020
  • Panossian A, Seo EJ, Klauck SM, Efferth T. Adaptogens in chemobrain (part IV): adaptogenic plants prevent the chemotherapeutics-induced imbalance of redox homeostasis by modulation of expression of genes encoding Nrf2-mediated signaling proteins and antioxidant, metabolizing, detoxifying enzymes in neuroglia cells. Longhua Chin Med 3:4, 2020
  • Yousaf A, Waltes R, Haslinger D, Klauck SM, Duketis E, Sachse M, Voran A, Biscaldi M, Schulte-Rüther M, Cichon S, Nöthen M, Ackermann J, Koch I, Freitag CM, Chiocchetti AG. Quantitative genome-wide association study of six phenotypic subdomains identifies novel genome-wide significant variants in autism spectrum disorder. Transl Psychiatry 10(1):215, 2020
  • Lin BD, Colas F, Nijman IJ, Medic J, Brands W, Parr JR, van Eijk KR, Klauck SM, Chiocchetti AG, Freitag CM, Maestrini E, Bacchelli E, Coon H, Vicente A, Oliveira G, Pagnamenta AT, Gallagher L, Ennis S, Anney R, Bourgeron T, Luykx JJ, Vorstman J. The role of rare compound heterozygous events in autism spectrum disorder. Transl Psychiatry 10(1):204, 2020

2019

  • Dietz S, Christopoulos P, Gu L, Volckmar AL, Endris V, Yuan Z, Ogrodnik SJ, Zemojtel T, Heussel CP, Schneider MA, Meister M, Muley T, Reck M, Schlesner M, Thomas M, Stenzinger A, Sültmann H. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK rearranged lung cancer. Cold Spring Harb Mol Case Stud 5(6):a004630, 2019
  • Dietz S, Lifshitz A, Kazdal D, Harms A, Endris V, Winter H, Stenzinger A, Warth A, Sill M, Tanay A, Sültmann H. Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas. Int J Cancer 144(5):1061-1072, 2019
  • Dietz S, Kazdal D, Sültmann H. Multiple layers of intratumor heterogeneity: clues to clonal evolution of non-small cell lung cancer. Oncotarget 10(16):1549-1551, 2019
  • Jenzer M, Kess P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S. The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunol Immunother 68(10):1621-1633, 2019
  • Willbold R, Wirth K, Martini T, Sültmann H, Bolenz C, Wittig R. Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells. Cell Death Dis 10(8):601, 2019; Correction: 11(2):120, 2020
  • Christopoulos P, Budczies J, Kirchner M, Dietz S, Sültmann H, Thomas M, Stenzinger A. Defining molecular risk in ALK(+) NSCLC. Oncotarget 10(33):3093-3103, 2019
  • Christopoulos P, Dietz S, Kirchner M, Volckmar AL, Endris V, Neumann O, Ogrodnik S, Heussel CP, Herth FJ, Eichhorn M, Meister M, Budczies J, Allgäuer M, Leichsenring J, Zemojtel T, Bischoff H, Schirmacher P, Thomas M, Sültmann H, Stenzinger A. Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. Cancers (Basel) 11(1):124, 2019
  • Weber R, Meister M, Muley T, Thomas M, Sültmann H, Warth A, Winter H, Herth FJF, Schneider MA. Pathways regulating the expression of the immunomodulatory protein glycodelin in nonsmall cell lung cancer. Int J Oncol 54(2):515-526, 2019
  • Volckmar AL, Endris V, Gaida MM, Leichsenring J, Stögbauer F, Allgäuer M, von Winterfeld M, Penzel R, Kirchner M, Brandt R, Neumann O, Sültmann H, Schirmacher P, Rudi J, Schmitz D, Stenzinger A. Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. Genes Chromosomes Cancer 58(1):3-11, 2019
  • Kazdal D, Longuespée R, Dietz S, Casadonte R, Schwamborn K, Volckmar AL, Kriegsmann J, Kriegsmann K, Fresnais M, Stenzinger A, Sültmann H, Warth A, Kriegsmann M. Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma. Proteomics Clin Appl 13(1):e1800034, 2019
  • Seo EJ, Klauck SM, Efferth T, Panossian A. Adaptogens in chemobrain (Part I): Plant extracts attenuate cancer chemotherapy-induced cognitive impairment - Transcriptome-wide microarray profiles of neuroglia cells. Phytomedicine 55:80-91, 2019
  • Seo EJ, Klauck SM, Efferth T, Panossian A. Adaptogens in chemobrain (Part II): Effect of plant extracts on chemotherapy-induced cytotoxicity in neuroglia cells. Phytomedicine 58: 152743, 2019
  • Seo EJ, Klauck SM, Efferth T, Panossian A. Adaptogens in chemobrain (Part III): Antitoxic effects of plant extracts towards cancer chemotherapy-induced toxicity - transcriptome-wide microarray analysis of neuroglia cells. Phytomedicine 56:246-260, 2019
  • Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, Pallesen J, Agerbo E, Andreassen OA, Anney R, Awashti S, Belliveau R, Bettella F, Buxbaum JD, Bybjerg-Grauholm J, Baekvad-Hansen M, Cerrato F, Chambert K, Christensen JH, Churchhouse C, Dellenvall K, Demontis D, De Rubeis S, Devlin B, Djurovic S, Dumont AL, Goldstein JI, Hansen CS, Hauberg ME, Hollegaard MV, Hope S, Howrigan DP, Huang H, Hultman CM, Klei L, Maller J, Martin J, Martin AR, Moran JL, Nyegaard M, Naerland T, Palmer DS, Palotie A, Pedersen CB, Pedersen MG, dPoterba T, Poulsen JB, Pourcain BS, Qvist P, Rehnström K, Reichenberg A, Reichert J, Robinson EB, Roeder K, Roussos P, Saemundsen E, Sandin S, Satterstrom FK, Davey Smith G, Stefansson H, Steinberg S, Stevens CR, Sullivan PF, Turley P, Walters GB, Xu X, Autism Spectrum Disorder Working Group of the Psychiatric Genomics Consortium, BUPGEN, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, 23andMe Research Team, Stefansson K, Geschwind DH, Nordentoft M, Hougaard DM, Werge T, Mors O, Mortensen PB, Neale BM, Daly MJ, Borglum AD. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet 51(3):431-444, 2019

2018

  • Angeles AK, Bauer S, Ratz L, Klauck SM, Sültmann H. Genome-based classification and therapy of prostate cancer. Diagnostics (Basel) 8(3):62, 2018
  • Volckmar AL, Sültmann H, Riediger A, Fioretos T, Schirmacher P, Endris V, Stenzinger A, Dietz S. A field guide for cancer diagnostics using cell-free DNA: from principles to practice and clinical applications. Genes Chromosomes Cancer 57(3):123-139, 2018
  • Tichy D, Pickl JMA, Benner A, Sültmann H. Experimental design and data analysis of Ago-RIP-Seq experiments for the identification of microRNA targets. Brief Bioinform 19(5):918-929, 2018
  • Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J. Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell 34(6):996-1011, 2018
  • Kesch C, Radtke JP, Wintsche A, Wiesenfarth M, Luttje M, Gasch C, Dieffenbacher S, Pecqueux C, Teber D, Hatiboglu G, Nyarangi-Dix J, Simpfendörfer T, Schönberg G, Dimitrakopoulou-Strauss A, Freitag M, Duensing A, Grüllich C, Jäger D, Götz M, Grabe N, Schweiger MR, Pahernik S, Perner S, Herpel E, Roth W, Wieczorek K, Maier-Hein K, Debus J, Haberkorn U, Giesel F, Galle J, Hadaschik B, Schlemmer HP, Hohenfellner M, Bonekamp D, Sültmann H, Duensing S. Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. Sci Rep 8(1):16708, 2018
  • Zabeck H, Dienemann H, Hoffmann H, Pfannschmidt J, Warth A, Schnabel PA, Muley T, Meister M, Sültmann H, Fröhlich H, Kuner R, Lasitschka F. Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma. PLoS One 13(10):e0206132, 2018
  • Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer. Urol Oncol 36(8):365 e315-365 e326, 2018
  • Grasse S, Lienhard M, Frese S, Kerick M, Steinbach A, Grimm C, Hussong M, Rolff J, Becker M, Dreher F, Schirmer U, Boerno S, Ramisch A, Leschber G, Timmermann B, Grohé C, Lüders H, Vingron M, Fichtner I, Klein S, Odenthal M, Büttner R, Lehrach H, Sültmann H, Herwig R, Schweiger MR. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. Genome Med 10(1):55, 2018
  • Dieffenbacher S, Zschäbitz S, Hofer L, Hatiboglu G, Hou W, Hohenfellner M, Duensing S, Sültmann H, Pahernik S, Grüllich C. Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL. Future Sci OA 4(5):FSO299, 2018
  • Zhang Z, Filzmayer C, Ni Y, Sültmannn H, Mutz P, Hiet M-S, Vondran FWR, Bartenschlager R, Urban S. Hepatitis D Virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes. J Hepatol 69(1):25-35, 2018
  • Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S. Genomic features of renal cell carcinoma with venous tumor thrombus. Sci Rep 8(1):7477, 2018
  • Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. Urol Oncol 36(4):161.e19-161.e30, 2018
  • Honegger A, Schilling D, Sültmann H, Hoppe-Seyler K, Hoppe-Seyler F. Identification of E6/E7-dependent microRNAs in HPV-positive cancer cells. Methods Mol Biol 1699:119-134, 2018
  • Mahmoud N, Saeed MEM, Sugimoto Y, Klauck SM, Greten HJ, Efferth T. Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation. Oncotarget 9(87):35762-35779, 2018
  • Chiocchetti AG, Yousaf A, Bour HS, Haslinger D, Waltes R, Duketis E, Jarczok T, Sachse M, Biscaldi M, Degenhardt F, Herms S, Cichon S, Ackermann J, Koch I, Klauck SM, Freitag CM. Common functional variants of the glutamatergic system in Autism spectrum disorder with high and low intellectual abilities. J Neural Transm (Vienna) 125(2):259-271, 2018
  • Brainstorm Consortium, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, Malik R, Patsopoulos NA, Ripke S, Wei Z, Yu D, Lee PH, Turley P, ..., Klauck SM, ..., Cheng W, Cloninger R, Curtis D, Gejman PV, Henskens F, Mattingsdal M, Oh SY, Scott R, Webb B, Breen G, Churchhouse C, Bulik CM, Daly M, Dichgans M, Faraone SV, Guerreiro R, Holmans P, Kendler KS, Koeleman B, Mathews CA, Price A, Scharf J, Sklar P, Williams J, Wood NW, Cotsapas C, Palotie A, Smoller JW, Sullivan P, Rosand J, Corvin A, Neale BM. Analysis of shared heritability in common disorders of the brain. Science 360(6395), eaap8757, 2018

2017

  • Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S. Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget 8(43):74049-74057, 2017
  • Dietz S, Harms A, Endris V, Eichhorn F, Kriegsmann M, Longuespée R, Stenzinger A, Sültmann H, Warth A, Kazdal D. Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas. Int J Cancer 141(9):1841-1848, 2017
  • Ratz L, Laible M, Kacprzyk LA, Wittig-Blaich SM, Tolstov Y, Duensing S, Altevogt P, Klauck SM, Sültmann H. TMPRSS2:ERG gene fusion variants induce TGF-ß signaling and epithelial to mesenchymal transition in human prostate cancer cells. Oncotarget 8(15):25115-25130, 2017
  • Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Mutations in BRCA2 and taxane resistance in prostate cancer. Sci Rep 7(1):4574, 2017
  • Lienhard M, Grasse S, Rolff J, Frese S, Schirmer U, Becker M, Börno S, Timmermann B, Chavez L, Sültmann H, Leschber G, Fichtner I, Schweiger MR, Herwig R. QSEA-modelling of genome-wide DNA methylation from sequencing enrichment experiments. Nucleic Acids Res 45(6):e44, 2017
  • Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. PARP inhibition in BRCA2-mutated prostate cancer. Ann Oncol 28(1):189-191, 2017
  • Hong C, Cao J, Wu CF, Kadioglu O, Schüffler A, Kauhl U, Klauck SM, Opatz T, Thines E, Paul NW, Efferth T. The Chinese herbal formula Free and Easy Wanderer ameliorates oxidative stress through KEAP1-NRF2/HO-1 pathway. Sci Rep 7(1):11551, 2017
  • Weiner DJ, Wigdor EM, Ripke S, Walters RK, Kosmicki JA, Grove J, Samocha KE, Goldstein JI, Okbay A, Bybjerg-Grauholm J, Werge T, Hougaard DM, Taylor J, iPSYCH-Broad Autism Group, Psychiatric Genomics Consortium Autism Group, Skuse D, Devlin B, Anney R, Sanders SJ, Bishop S, Mortensen PB, Borglum AD, Smith GD, Daly MJ, Robinson EB. Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders. Nat Genet 49(7):978-985, 2017
  • Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium. Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. Mol Autism 8:21, 2017
  • Müller S, Von Bubnoff N, Dietz S, Sültmann H. Liquid Biopsy bei Krebserkrankungen - Möglichkeiten und Grenzen der Tumor-Verlaufs-Kontrolle. GIT Labor-Fachzeitschrift 61(8):23-25, 2017

2016

  • Riediger AL, Dietz S, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, Muley T, Thomas M, Sültmann H. Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. Sci Rep 6:33505, 2016
  • Pickl JM, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Schüler J, Reidenbach D, Hotz-Wagenblatt A, Kristiansen G, Roth W, Hadaschik B, Hohenfellner M, Duensing S, Heckmann D, Sültmann H. Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget 7(37):59589-59603, 2016
  • Dietz S, Schirmer U, Mercé C, von Bubnoff N, Dahl E, Meister M, Muley T, Thomas M, Sültmann H. Low input whole-exome sequencing to determine the representation of the tumor exome in circulating DNA of non-small cell lung cancer patients. PLoS One 11(8):e0161012, 2016
  • Castelo-Branco P, Leao R, Lipman T, Campbell B, Lee D, Price A, Zhang C, Heidari A, Stephens D, Boerno S, Coelho H, Gomes A, Domingos C, Apolonio JD, Schäfer G, Bristow RG, Schweiger MR, Hamilton R, Zlotta A, Figueiredo A, Klocker H, Sültmann H, Tabori U. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: A retrospective cohort study. Oncotarget 7(36):57726-57736, 2016
  • Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S. Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nat Commun 7:ncomms11845, 2016
  • Praveen P, Hülsmann H, Sültmann H, Kuner R, Fröhlich H. Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer. Sci Rep 6:27514, 2016
  • Wu CF, Seo EJ, Klauck SM, Efferth T. Cryptotanshinone deregulates unfolded protein response and eukaryotic initiation factor signaling in acute lymphoblastic leukemia cells. Phytomedicine 23(2):174-180, 2016
  • Wu CF, Klauck SM, Efferth T. Anticancer activity of cryptotanshinone on acute lymphoblastic leukemia cells. Arch Toxicol 90(9):2275-2286, 2016
  • Prins BP, Abbasi A, Wong A, Vaez A, Nolte I, Franceschini N, Stuart PE, Guterriez Achury J, Mistry V, Bradfield JP, Valdes AM, Bras J, Shatunov A, PAGE Consortium, International Stroke Genetics Consortium, Systemic Sclerosis consortium, Treat OA consortium, DIAGRAM Consortium, CARDIoGRAMplusC4D Consortium, ALS consortium, International Parkinson's Disease Genomics Consortium, Autism Spectrum Disorder Working Group of the Psychiatric Genomics Consortium, CKDGen consortium, GERAD1 Consortium, International Consortium for Blood Pressure, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Inflammation Working Group of the CHARGE Consortium, Lu C, Han B, Raychaudhuri S, Bevan S, Mayes MD, Tsoi LC, Evangelou E, Nair RP, Grant SFA, Polychronakos C, Radstake TRD, van Heel DA, Dunstan ML, Wood NW, Al-Chalabi A, Dehghan A, Hakonarson H, Markus HS, Elder JT, Knight J, Arking DE, Spector TD, Koeleman BPC, van Duijn CM, Martin J, Morris AP, Weersma RK, Wijmenga C, Munroe PB, Perry JRB, Pouget JG, Jamshidi Y, Snieder H, Alizadeh BZ. Investigating the causal relationship of C-Reactive Protein with 32 complex somatic and psychiatric outcomes: A large-scale cross-consortium Mendelian randomization study. PLoS Med 13(6):e1001976, 2016
  • Minia I, Mercé C, Terrao M, Clayton C. Translation regulation and RNA granule formation after heat shock of procyclic form Trypanosoma brucei: Many heat-induced mRNAs are also increased during differentiation to mammalian-infective forms. PLoS Negl Trop Dis 10(9):e0004982, 2016
  • Antwi EB, Haanstra JR, Ramasamy G, Jensen B, Droll D, Rojas F, Minia I, Terrao M, Mercé C, Matthews K, Myler PJ, Parsons M, Clayton C. Integrative analysis of the Trypanosoma brucei gene expression cascade predicts differential regulation of mRNA processing and unusual control of ribosomal protein expression. BMC Genomics 17:306, 2016
  • Lueong S, Mercé C, Fischer B, Hoheisel JD, Erben ED. Gene expression regulatory networks in Trypanosoma brucei: insights into the role of the mRNA-binding proteome. Mol Microbiol 100(3):457-471, 2016

2015

  • Gu L, Frommel SC, Oakes CC, Simon R, Grupp K, Gerig CY, Bär D, Robinson MD, Baer C, Weiss M, Gu Z, Schapira M, Kuner R, Sültmann H, Provenzano M, Cancer IPoEOP, Yaspo ML, Brors B, Korbel J, Schlomm T, Sauter G, Eils R, Plass C, Santoro R. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nat Genet 47(1):22-30, 2015
  • Höfflin R, Roth W, Sültmann H, Grüllich C, Hatiboglu G, Nyarangi-Dix J, Schönberg G, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. [Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications]. Urologe A 54(6):800-803, 2015
  • Ridder K, Sevko A, Heide J, Dams M, Rupp AK, Macas J, Starmann J, Tjwa M, Plate KH, Sültmann H, Altevogt P, Umansky V, Momma S. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology 4(6):e1008371, 2015
  • Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sültmann H, Scheffner M, Hoppe-Seyler K, Hoppe-Seyler F. Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog 11(3):e1004712, 2015
  • Wu CF, Hong C, Klauck SM, Lin YL, Efferth T. Molecular mechanisms of rosmarinic acid from salvia miltiorrhiza in acute lymphoblastic leukemia cells. J Ethnopharmacol 176:55-68, 2015
  • Zhao Q, Assimopoulou AN, Klauck SM, Damianakos H, Chinou I, Kretschmer N, Rios JL, Papageorgiou VP, Bauer R, Efferth T. Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells. Oncotarget 6(36):38934-38951, 2015
  • Ceroni F, Simpson NH, Francks C, Baird G, Conti-Ramsden G, Clark A, Bolton PF, Hennessy ER, Donnelly P, Bentley DR, Martin H, IMGSAC, SLI Consortium, WGS500 Consortium, Parr J, Pagnamenta AT, Maestrini E, Bacchelli E, Fisher SE, Newbury DF. Reply to Pembrey et al: 'ZNF277 microdeletions, specific language impairment and the meiotic mismatch methylation (3M) hypothesis'. Eur J Hum Genet 23(9):1113-1115, 2015
  • Chiocchetti AG, Kopp M, Waltes R, Haslinger D, Duketis E, Jarczok TA, Poustka F, Voran A, Graab U, Meyer J, Klauck SM, Fulda S, Freitag CM. Variants of the CNTNAP2 5' promoter as risk factors for autism spectrum disorders: a genetic and functional approach. Mol Psychiatry 20(7):839-849, 2015
  • Heckmann D, Urban C, Weber K, Kannenberg K, Binder G. Decreased expression of cell proliferation-related genes in clonally derived skin fibroblasts from children with Silver-Russell syndrome is independent of the degree of 11p15 ICR1 hypomethylation. Clin Epigenetics 7(1):5, 2015
  • Maier R, Moser G, Chen GB, Ripke S, Cross-Disorder Working Group of the Psychiatric Genomics Consortium, Coryell W, Potash JB, Scheftner WA, Shi J, Weissman MM, Hultman CM, Landén M, Levinson DF, Kendler KS, Smoller JW, Wray NR, Lee SH. Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. Am J Hum Genet 96(2):283-294, 2015
  • Mulindwa J, Mercé C, Matovu E, Enyaru J, Clayton C. Transcriptomes of newly-isolated Trypanosoma brucei rhodesiense reveal hundreds of mRNAs that are co-regulated with stumpy-form markers. BMC Genomics 16(1):1118, 2015
  • Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 18(2):199-209, 2015
  • Pickl JM, Kamel W, Ciftci S, Punga T, Akusjärvi G. Opposite expression of CYP51A1 and its natural antisense transcript AluCYP51A1 in adenovirus type 37 infected retinal pigmented epithelial cells. FEBS Lett 589(12):1383-1388, 2015
  • Zanni G, Kalscheuer VM, Friedrich A, Barresi S, Alfieri P, Di Capua M, Haas SA, Piccini G, Karl T, Klauck SM, Bellacchio E, Emma F, Cappa M, Bertini E, Breitenbach-Koller L. A novel mutation in RPL10 (Ribosomal Protein L10) causes X-linked intellectual disability, cerebellar hypoplasia, and spondylo-epiphyseal dysplasia. Hum Mutat 36(12):1155-1158, 2015
  • Heckmann D, Sültmann H. Hochdurchsatz-Sequenzierung beim Prostatakarzinom. Uro-News 19(1):30-33, 2015
  • Dietz S, Riediger A, Thomas M, Schirmer U, Sültmann H. Chancen und Grenzen der "liquid biopsy“ für die Tumordiagnostik. BIOspektrum 21. Jahrgang(07.15):731-733, 2015

2014

  • Hülsmann HJ, Rolff J, Bender C, Jarahian M, Korf U, Herwig R, Fröhlich H, Thomas M, Merk J, Fichtner I, Sültmann H, Kuner R. Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib. Lung Cancer 86(2):151-157, 2014
  • Pickl JM, Heckmann D, Ratz L, Klauck SM, Sültmann H. Novel RNA markers in prostate cancer: functional considerations and clinical translation. Biomed Res Int 2014:765207, 2014
  • Georgi B, Korzeniewski N, Hadaschik B, Grüllich C, Roth W, Sültmann H, Pahernik S, Hohenfellner M, Duensing S. Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review). Int J Oncol 45(4):1337-1344, 2014
  • Sültmann H, Diederichs S. Long noncoding RNA: "LNCs" to cancer. Eur Urol 65(6):1152-1153, 2014
  • Hussong M, Börno ST, Kerick M, Wunderlich A, Franz A, Sültmann H, Timmermann B, Lehrach H, Hirsch-Kauffmann M, Schweiger MR. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. Cell Death Dis 5:e1195, 2014
  • Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146(4):1070-1083, 2014
  • Pandey V, Sultan M, Kashofer K, Ralser M, Amstislavskiy V, Starmann J, Osprian I, Grimm C, Hache H, Yaspo ML, Sültmann H, Trauner M, Denk H, Zatloukal K, Lehrach H, Wierling C. Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains. PLoS One 9(10):e111006, 2014
  • Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Turco DD, Starmann J, Macas J, Karpova D, Devraj K, Depboylu C, Landfried B, Arnold B, Plate KH, Höglinger G, Sültmann H, Altevogt P, Momma S. Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol 12(6):e1001874, 2014
  • Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P. Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget 5(2):462-472, 2014
  • Doberstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, Müller-Holzner E, Reimer D, Zeimet AG, Altevogt P. miR-21-3p is a positive regulator of L1CAM in several human carcinomas. Cancer Lett 354(2):455-466, 2014
  • Doberstein K, Milde-Langosch K, Bretz NP, Schirmer U, Harari A, Witzel I, Ben-Arie A, Hubalek M, Müller-Holzner E, Reinold S, Zeimet AG, Altevogt P, Fogel M. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. BMC Cancer 14:958, 2014
  • Heckmann D, Maier P, Laufs S, Li L, Sleeman JP, Trunk MJ, Leupold JH, Wenz F, Zeller WJ, Fruehauf S, Allgayer H. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1alpha-induced gene expression, invasion and chemosensitivity of colon cancer. Clin Cancer Res 20(3):604-616, 2014
  • Babbs C, Lloyd D, Pagnamenta AT, Twigg SR, Green J, McGowan SJ, Mirza G, Naples R, Sharma VP, Volpi EV, Buckle VJ, Wall SA, Knight SJ, International Molecular Genetic Study of Autism Consortium (IMGSAC), Parr JR, Wilkie AO. De novo and rare inherited mutations implicate the transcriptional coregulator TCF20/SPBP in autism spectrum disorder. J Med Genet 51(11):737-747, 2014
  • Bonora E, Graziano C, Minopoli F, Bacchelli E, Magini P, Diquigiovanni C, Lomartire S, Bianco F, Vargiolu M, Parchi P, Marasco E, Mantovani V, Rampoldi L, Trudu M, Parmeggiani A, Battaglia A, Mazzone L, Tortora G, IMGSAC, Maestrini E, Seri M, Romeo G. Maternally inherited genetic variants of CADPS2 are present in autism spectrum disorders and intellectual disability patients. EMBO Mol Med 6(6):795-809, 2014
  • Buxbaum JD, Bolshakova N, Brownfeld JM, Anney RJ, Bender P, Bernier R, Cook EH, Coon H, Cuccaro M, Freitag CM, Hallmayer J, Geschwind D, Klauck SM, Nurnberger JI, Oliveira G, Pinto D, Poustka F, Scherer SW, Shih A, Sutcliffe JS, Szatmari P, Vicente AM, Vieland V, Gallagher L. The Autism Simplex Collection: an international, expertly phenotyped autism sample for genetic and phenotypic analyses. Mol Autism 5:34, 2014
  • Ceroni F, Simpson NH, Francks C, Baird G, Conti-Ramsden G, Clark A, Bolton PF, Hennessy ER, Donnelly P, Bentley DR, Martin H, IMGSAC, SLI Consortium, WGS500 Consortium, Parr J, Pagnamenta AT, Maestrini E, Bacchelli E, Fisher SE, Newbury DF. Homozygous microdeletion of exon 5 in ZNF277 in a girl with specific language impairment. Eur J Hum Genet 22(10):1165-1171, 2014
  • Chiocchetti AG, Haslinger D, Boesch M, Karl T, Wiemann S, Freitag CM, Poustka F, Scheibe B, Bauer JW, Hintner H, Breitenbach M, Kellermann J, Lottspeich F, Klauck SM, Breitenbach-Koller L. Protein signatures of oxidative stress response in a patient specific cell line model for autism. Mol Autism 5(1):10, 2014
  • De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, Kou Y, Liu L, Fromer M, Walker S, Singh T, Klei L, Kosmicki J, Shih-Chen F, Aleksic B, Biscaldi M, Bolton PF, Brownfeld JM, Cai J, Campbell NG, Carracedo A, Chahrour MH, Chiocchetti AG, Coon H, Crawford EL, Curran SR, Dawson G, Duketis E, Fernandez BA, Gallagher L, Geller E, Guter SJ, Hill RS, Ionita-Laza J, Jimenz Gonzalez P, Kilpinen H, Klauck SM, Kolevzon A, Lee I, Lei I, Lei J, Lehtimaki T, Lin CF, Ma'ayan A, Marshall CR, McInnes AL, Neale B, Owen MJ, Ozaki N, Parellada M, Parr JR, Purcell S, Puura K, Rajagopalan D, Rehnström K, Reichenberg A, Sabo A, Sachse M, Sanders SJ, Schafer C, Schulte-Rüther M, Skuse D, Stevens C, Szatmari P, Tammimies K, Valladares O, Voran A, Li-San W, Weiss LA, Willsey AJ, Yu TW, Yuen RK, The DDD Study, Homozygosity Mapping Collaborative for Autism, UK10K Consortium, The Autism Sequencing Consortium, Cook EH, Freitag CM, Gill M, Hultman CM, Lehner T, Palotie A, Schellenberg GD, Sklar P, State MW, Sutcliffe JS, Walsh CA, Scherer SW, Zwick ME, Barett JC, Cutler DJ, Roeder K, Devlin B, Daly MJ, Buxbaum JD. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515(7526):209-215, 2014
  • Hadley D, Wu ZL, Kao C, Kini A, Mohamed-Hadley A, Thomas K, Vazquez L, Qiu H, Mentch F, Pellegrino R, Kim C, Connolly J, AGP Consortium, Glessner J, Hakonarson H. The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism. Nat Commun 5:4074, 2014
  • Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, Thiruvahindrapuram B, Xu X, Ziman R, Wang Z, Vorstman JA, Thompson A, Regan R, Pilorge M, Pellecchia G, Pagnamenta AT, Oliveira B, Marshall CR, Magalhaes TR, Lowe JK, Howe JL, Griswold AJ, Gilbert J, Duketis E, Dombroski BA, De Jonge MV, Cuccaro M, Crawford EL, Correia CT, Conroy J, Conceicao IC, Chiocchetti AG, Casey JP, Cai G, Cabrol C, Bolshakova N, Bacchelli E, Anney R, Gallinger S, Cotterchio M, Casey G, Zwaigenbaum L, Wittemeyer K, Wing K, Wallace S, van Engeland H, Tryfon A, Thomson S, Soorya L, Rogé B, Roberts W, Poustka F, Mouga S, Minshew N, McInnes LA, McGrew SG, Lord C, Leboyer M, Le Couteur AS, Kolevzon A, Jimenez González P, Jacob S, Holt R, Guter S, Green J, Green A, Gillberg C, Fernandez BA, Duque F, Delorme R, Dawson G, Chaste P, Café C, Brennan S, Bourgeron T, Bolton PF, Bölte S, Bernier R, Baird G, Bailey AJ, Anagnostou E, Almeida J, Wijsman EM, Vieland VJ, Vicente AM, Schellenberg GD, Pericak-Vance M, Paterson AD, Parr JR, Oliveira G, Nurnberger JI, Monaco AP, Maestrini E, Klauck SM, Hakonarson H, Haines JL, Geschwind DH, Freitag CM, Folstein SE, Ennis S, Coon H, Battaglia A, Szatmari P, Sutcliffe JS, Hallmayer J, Gill M, Cook EH, Buxbaum JD, Devlin B, Gallagher L, Betancur C, Scherer SW. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet 94(5):677-694, 2014
  • Waltes R, Duketis E, Knapp M, Anney RJ, Huguet G, Schlitt S, Jarczok TA, Sachse M, Kämpfer LM, Kleinböck T, Poustka F, Bölte S, Schmötzer G, Voran A, Huy E, Meyer J, Bourgeron T, Klauck SM, Freitag CM, Chiocchetti AG. Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders. Hum Genet 133(6):781-792, 2014

2013

  • Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Hass T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23(2):159-170, 2013
  • Kacprzyk LA, Laible M, Andrasiuk T, Brase JC, Börno ST, Fälth M, Kuner R, Lehrach H, Schweiger MR, Sültmann H. ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer. PLoS One 8(3):e59976, 2013
  • Kaduthanam S, Gade S, Meister M, Brase JC, Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sültmann H, Muley T, Kuner R. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 80(2):223-227, 2013
  • Kuner R, Brase JC, Sültmann H, Wuttig D. microRNA biomarkers in body fluids of prostate cancer patients. Methods 59(1):132-137, 2013
  • Kuner R, Fälth M, Pressinotti NC, Brase JC, Puig SB, Metzger J, Gade S, Schäfer G, Bartsch G, Steiner E, Klocker H, Sültmann H. The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl) 91(2):237-248, 2013
  • Massoner P, Kugler KG, Unterberger K, Kuner R, Mueller LA, Fälth M, Schäfer G, Seifarth C, Ecker S, Verdorfer I, Graber A, Sültmann H, Klocker H. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y. PLoS One 8(2):e55207, 2013
  • Gottschling S, Granzow M, Kuner R, Jauch A, Herpel E, Xu EC, Muley T, Schnabel PA, Herth FJ, Meister M. Mesenchymal stem cells in non-small cell lung cancer--different from others? Insights from comparative molecular and functional analyses. Lung Cancer 80(1):19-29, 2013
  • Hadaschik B, Pahernik S, Grüllich C, Sültmann H, Jäger D, von Kalle C, Duensing S, Hohenfellner M. [Urology in the concept of comprehensive cancer centers]. Urologe A 52(9):1283-1289, 2013
  • Hellwinkel OJ, Sellier C, Sylvester YM, Brase JC, Isbarn H, Erbersdobler A, Steuber T, Sültmann H, Schlomm T, Wagner C. A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue. Int J Mol Sci 14(3):5239-5249, 2013
  • Jarius S, Martinez-Garcia P, Hernandez AL, Brase JC, Borowski K, Regula JU, Meinck HM, Stöcker W, Wildemann B, Wandinger KP. Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. J Neuroinflammation 10:7, 2013
  • Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A, Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, Andreassen OA, Anjorin A, Anney R, Anttila V, Arking DE, Asherson P, Azevedo MH, Backlund L, Badner JA, Bailey AJ, Banaschewski T, Barchas JD, Barnes MR, Barrett TB, Bass N, Battaglia A, Bauer M, Bayés M, Bellivier F, Bergen SE, Berrettini W, Betancur C, Bettecken T, Biederman J, Binder EB, Black DW, Blackwood DH, Bloss CS, Boehnke M, Boomsma DI, Breen G, Breuer R, Bruggeman R, Cormican P, Buccola NG, Buitelaar JK, Bunney WE, Buxbaum JD, Byerley WF, Byrne EM, Caesar S, Cahn W, Cantor RM, Casas M, Chakravarti A, Chambert K, Choudhury K, Cichon S, Cloninger CR, Collier DA, Cook EH, Coon H, Cormand B, Corvin A, Coryell WH, Craig DW, Craig IW, Crosbie J, Cuccaro ML, Curtis D, Czamara D, Datta S, Dawson G, Day R, De Geus EJ, Degenhardt F, Djurovic S, Donohoe GJ, Doyle AE, Duan J, Dudbridge F, Duketis E, Ebstein RP, Edenberg HJ, Elia J, Ennis S, Etain B, Fanous A, Farmer AE, Ferrier IN, Flickinger M, Fombonne E, Foroud T, Frank J, Franke B, Fraser C, Freedman R, Freimer NB, Freitag CM, Friedl M, Frisen L, Gallagher L, Gejman PV, Georgieva L, Gershon ES, Geschwind DH, Giegling I, Gill M, Gordon SD, Gordon-Smith K, Green EK, Greenwood TA, Grice DE, Gross M, Grozeva D, Guan W, Gurling H, De Haan L, Haines JL, Hakonarson H, Hallmayer J, Hamilton SP, Hamshere ML, Hansen TF, Hartmann AM, Hautzinger M, Heath AC, Henders AK, Herms S, Hickie IB, Hipolito M, Hoefels S, Holmans PA, Holsboer F, Hoogendijk WJ, Hottenga JJ, Hultman CM, Hus V, Ingason A, Ising M, Jamain S, Jones EG, Jones I, Jones L, Tzeng JY, Kahler AK, Kahn RS, Kandaswamy R, Keller MC, Kennedy JL, Kenny E, Kent L, Kim Y, Kirov GK, Klauck SM, Klei L, Knowles JA, Kohli MA, Koller DL, Konte B, Korszun A, Krabbendam L, Krasucki R, Kuntsi J, Kwan P, Landén M, Langström N, Lathrop M, Lawrence J, Lawson WB, Leboyer M, Ledbetter DH, Lee PH, Lencz T, Lesch KP, Levinson DF, Lewis CM, Li J, Lichtenstein P, Lieberman JA, Lin DY, Linszen DH, Liu C, Lohoff FW, Loo SK, Lord C, Lowe JK, Lucae S, MacIntyre DJ, Madden PA, Maestrini E, Magnusson PK, Mahon PB, Maier W, Malhotra AK, Mane SM, Martin CL, Martin NG, Mattheisen M, Matthews K, Mattingsdal M, McCarroll SA, McGhee KA, McGough JJ, McGrath PJ, McGuffin P, McInnis MG, McIntosh A, McKinney R, McLean AW, McMahon FJ, McMahon WM, McQuillin A, Medeiros H, Medland SE, Meier S, Melle I, Meng F, Meyer J, Middeldorp CM, Middleton L, Milanova V, Miranda A, Monaco AP, Montgomery GW, Moran JL, Moreno-De-Luca D, Morken G, Morris DW, Morrow EM, Moskvina V, Muglia P, Muhleisen TW, Muir WJ, Muller-Myhsok B, Murtha M, Myers RM, Myin-Germeys I, Neale MC, Nelson SF, Nievergelt CM, Nikolov I, Nimgaonkar V, Nolen WA, Nöthen MM, Nurnberger JI, Nwulia EA, Nyholt DR, O'Dushlaine C, Oades RD, Olincy A, Oliveira G, Olsen L, Ophoff RA, Osby U, Owen MJ, Palotie A, Parr JR, Paterson AD, Pato CN, Pato MT, Penninx BW, Pergadia ML, Pericak-Vance MA, Pickard BS, Pimm J, Piven J, Posthuma D, Potash JB, Poustka F, Propping P, Puri V, Quested DJ, Quinn EM, Ramos-Quiroga JA, Rasmussen HB, Raychaudhuri S, Rehnström K, Reif A, Ribasés M, Rice JP, Rietschel M, Roeder K, Roeyers H, Rossin L, Rothenberger A, Rouleau G, Ruderfer D, Rujescu D, Sanders AR, Sanders SJ, Santangelo SL, Sergeant JA, Schachar R, Schalling M, Schatzberg AF, Scheftner WA, Schellenberg GD, Scherer SW, Schork NJ, Schulze TG, Schumacher J, Schwarz M, Scolnick E, Scott LJ, Shi J, Shilling PD, Shyn SI, Silverman JM, Slager SL, Smalley SL, Smit JH, Smith EN, Sonuga-Barke EJ, St Clair D, State M, Steffens M, Steinhausen HC, Strauss JS, Strohmaier J, Stroup TS, Sutcliffe JS, Szatmari P, Szelinger S, Thirumalai S, Thompson RC, Todorov AA, Tozzi F, Treutlein J, Uhr M, van den Oord EJ, Van Grootheest G, Van Os J, Vicente AM, Vieland VJ, Vincent JB, Visscher PM, Walsh CA, Wassink TH, Watson SJ, Weissman MM, Werge T, Wienker TF, Wijsman EM, Willemsen G, Williams N, Willsey AJ, Witt SH, Xu W, Young AH, Yu TW, Zammit S, Zandi PP, Zhang P, Zitman FG, Zöllner S, International Inflammatory Bowel Disease Genetics Consortium (IIBDGC), Devlin B, Kelsoe JR, Sklar P, Daly MJ, O'Donovan MC, Craddock N, Sullivan PF, Smoller JW, Kendler KS, Wray NR. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 45(9):984-994, 2013
  • Klauck SM, Hallmayer J. Molekularbiologische Methoden. In: Lehmkuhl G, Poustka F, Holtmann M, Steiner H, eds. Lehrbuch der Kinder- und Jugendpsychiatrie: Hogrefe Verlag GmbH & Ko. KG; 2013:332-345.
  • Kaduthanam S, Kuner R, Meister M, Muley T, Sültmann H. Research Highlight. DZL Annual Report (German and English Issues):68, 2013
  • Kuner R, Sültmann H. Operation ja oder nein: Neue Serum-Biomarker indizieren Prostatakrebs-Therapie. Best of 2012/13, NGFN-plus & NGFN-transfer:3, 2013

2012

  • Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Röhr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sültmann H, Lehrach H, Schweiger MR. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2(11):1024-1035, 2012
  • Kahn N, Meister M, Eberhardt R, Muley T, Schnabel PA, Bender C, Johannes M, Keitel D, Sültmann H, Herth FJ, Kuner R. Early detection of lung cancer by molecular markers in endobronchial epithelial-lining fluid. J Thorac Oncol 7(6):1001-1008, 2012
  • Starmann J, Fälth M, Spindelböck W, Lanz KL, Lackner C, Zatloukal K, Trauner M, Sültmann H. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One 7(10):e46584, 2012
  • Gottschling S, Jauch A, Kuner R, Herpel E, Mueller-Decker K, Schnabel PA, Xu EC, Muley T, Sültmann H, Bender C, Granzow M, Efferth T, Hoffmann H, Dienemann H, Herth FJ, Meister M. Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue. Lung Cancer 75(1):45-57, 2012
  • Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger HA, Brase JC, Kuner R, Schlomm T, Sauter G, Sültmann H, Korf U, Bokemeyer C, Walther R, Brümmendorf TH, Balabanov S. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res 11(4):2452-2466, 2012
  • Wuttig D, Zastrow S, Füssel S, Toma MI, Meinhardt M, Kalman K, Junker K, Sanjmyatav J, Boll K, Hackermüller J, Rolle A, Grimm MO, Wirth MP. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer 131(5):E693-704, 2012
  • Nilsson A, Stroth N, Zhang X, Qi H, Fälth M, Sköld K, Hoyer D, Andrén PE, Svenningsson P. Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects. Neuropharmacology 62(1):347-357, 2012
  • Sultan M, Dökel S, Amstislavskiy V, Wuttig D, Sültmann H, Lehrach H, Yaspo ML. A simple strand-specific RNA-Seq library preparation protocol combining the Illumina TruSeq RNA and the dUTP methods. Biochem Biophys Res Commun 422(4):643-646, 2012
  • Zacher B, Abnaof K, Gade S, Younesi E, Tresch A, Fröhlich H. Joint Bayesian inference of condition-specific miRNA and transcription factor activities from combined gene and microRNA expression data. Bioinformatics 28(13):1714-1720, 2012
  • Kaduthanam S, Kuner R, Meister M, Muley T, Sültmann H. Research Highlight. DZL Annual Report (German and English Issues):50, 2012
  • Weber U, Siebert R, Sültmann H, Wuttig D. ICGC - das Internationale Krebsgenom-Konsortium: Auf dem Weg zu individualisierten Krebstherapien. Systembiologie.DE 04:22-27, 2012

2011

  • Brase JC, Johannes M, Mannsperger H, Fälth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H, Sauter G, Simon R, Schlomm T, Beissbarth T, Korf U, Kuner R, Sültmann H. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 11(1):507, 2011
  • Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sültmann H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128(3):608-616, 2011
  • Brase JC, Mannsperger H, Sültmann H, Korf U. Antibody-mediated signal amplification for reverse phase protein array-based protein quantification. Methods Mol Biol 785:55-64, 2011
  • Bu H, Bormann S, Schäfer G, Horninger W, Massoner P, Neeb A, Lakshmanan VK, Maddalo D, Nestl A, Sültmann H, Cato AC, Klocker H. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 71(6):575-587, 2011
  • Gade S, Porzelius C, Fälth M, Brase JC, Wuttig D, Kuner R, Binder H, Sültmann H, Beissbarth T. Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer. BMC Bioinformatics 12(1):488, 2011
  • Hellwinkel OJ, Asong LE, Rogmann JP, Sültmann H, Wagner C, Schlomm T, Eichelberg C. Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma. Prostate Cancer Prostatic Dis 14(1):38-45, 2011
  • Johannes M, Fröhlich H, Sültmann H, Beissbarth T. pathClass: an R-package for integration of pathway knowledge into support vector machines for biomarker discovery. Bioinformatics 27(10):1442-1443, 2011
  • Wittig-Blaich SM, Kacprzyk LA, Eismann T, Bewerunge-Hudler M, Kruse P, Winkler E, Strauss WS, Hibst R, Steiner R, Schrader M, Mertens D, Sültmann H, Wittig R. Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells. Neoplasia 13(7):579-589, 2011
  • Kerick M, Isau M, Timmermann B, Sültmann H, Herwig R, Krobitsch S, Schaefer G, Verdorfer I, Bartsch G, Klocker H, Lehrach H, Schweiger MR. Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics 4:68, 2011
  • Rupp AK, Rupp C, Keller S, Brase JC, Ehehalt R, Fogel M, Moldenhauer G, Marmé F, Sültmann H, Altevogt P. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecol Oncol 122(2):437-446, 2011
  • Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 17(18):5878-5888, 2011
  • Ummanni R, Jost E, Braig M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C, Sültmann H, Meyer-Schwesinger C, Brümmendorf TH, Balabanov S. Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation. Mol Cancer 10:129, 2011
  • Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, Fälth M, Köllermann J, Walther R, Schlomm T, Sauter G, Bokemeyer C, Sültmann H, Schuppert A, Brümmendorf TH, Balabanov S. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform. PLoS One 6(2):e16833, 2011
  • Warth A, Muley T, Meister M, Herpel E, Pathil A, Hoffmann H, Schnabel PA, Bender C, Buness A, Schirmacher P, Kuner R. Loss of aquaporin-4 expression and putative function in non-small cell lung cancer. BMC Cancer 11:161, 2011
  • Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Fälth M, Sültmann H, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One 6(7):e21651, 2011
  • Hanrieder J, Ljungdahl A, Fälth M, Mammo SE, Bergquist J, Andersson M. L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Mol Cell Proteomics 10(10):M111 009308, 2011
  • Ljungdahl A, Hanrieder J, Fälth M, Bergquist J, Andersson M. Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease. PLoS One 6(9):e25653, 2011
  • Porzelius C, Johannes M, Binder H, Beissbarth T. Leveraging external knowledge on molecular interactions in classification methods for risk prediction of patients. Biom J 53(2):190-201, 2011
  • Wuttig D, Sültmann H. Genomsequenzierung von Prostattumoren. Laborwelt 12(2):19-20, 2011

2010

  • Brase JC, Mannsperger H, Fröhlich H, Gade S, Schmidt C, Wiemann S, Beissbarth T, Schlomm T, Sültmann H, Korf U. Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification. Proteome Sci 8:36, 2010
  • Brase JC, Wuttig D, Kuner R, Sültmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9:306, 2010
  • Johannes M, Brase JC, Fröhlich H, Gade S, Gehrmann M, Fälth M, Sültmann H, Beissbarth T. Integration of pathway knowledge into a reweighted recursive feature elimination approach for risk stratification of cancer patients. Bioinformatics 26(17):2136-2144, 2010
  • Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 16(8):2391-2401, 2010
  • Mannsperger HA, Gade S, Henjes F, Beissbarth T, Korf U. RPPanalyzer: Analysis of reverse-phase protein array data. Bioinformatics 26(17):2202-2203, 2010
  • Youns M, Fu YJ, Zu YG, Kramer A, Konkimalla VB, Radlwimmer B, Sültmann H, Efferth T. Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics. Naunyn Schmiedebergs Arch Pharmacol 382(3):221-234, 2010

2009

  • Calabrò A, Beissbarth T, Kuner R, Stojanov M, Benner A, Asslaber M, Ploner F, Zatloukal K, Samonigg H, Poustka A, Sültmann H. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 116(1):69-77, 2009
  • Pressinotti NC, Klocker H, Schäfer G, Luu VD, Ruschhaupt M, Kuner R, Steiner E, Poustka A, Bartsch G, Sültmann H. Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer 8:130, 2009
  • Schlomm T, Hellwinkel OJ, Buness A, Ruschhaupt M, Lübke AM, Chun FK, Simon R, Budäus L, Erbersdobler A, Graefen M, Huland H, Poustka A, Sültmann H. Molecular cancer phenotype in normal prostate tissue. Eur Urol 55(4):885-890, 2009
  • Sers C, Kuner R, Falk CS, Lund P, Sueltmann H, Braun M, Buness A, Ruschhaupt M, Conrad J, Mang-Fatehi S, Stelniec I, Krapfenbauer U, Poustka A, Schäfer R. Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer 125(7):1626-1639, 2009
  • Kahn N, Kuner R, Eberhardt R, Meister M, Muley T, Winteroll S, Schnabel PA, Ishizaka A, Herth FJ, Poustka A, Sültmann H, Hoffmann H. Gene expression analysis of endobronchial epithelial lining fluid in the evaluation of indeterminate pulmonary nodules. J Thorac Cardiovasc Surg 138(2):474-479, 2009
  • Korf U, Löbke C, Sahin O, Haller F, Sültmann H, Arlt D, Poustka A. Reverse-phase protein arrays for application-orientated cancer research. Proteomics Clin Appl 3(10):1140-1150, 2009
  • Kuner R, Muley T, Meister M, Ruschhaupt M, Buness A, Xu EC, Schnabel P, Warth A, Poustka A, Sültmann H, Hoffmann H. Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer 63(1):32-38, 2009
  • Schlomm T, Sültmann H, Köllermann J. [Identification and validation of clinically relevant molecular alterations in prostate cancer]. Pathologe 30(2):111-116, 2009
  • Hagist S, Sültmann H, Millonig G, Hebling U, Kieslich D, Kuner R, Balaguer S, Seitz HK, Poustka A, Mueller S. In vitro-targeted gene identification in patients with hepatitis C using a genome-wide microarray technology. Hepatology 49(2):378-386, 2009
  • Koncarevic S, Urig S, Steiner K, Rahlfs S, Herold-Mende C, Sueltmann H, Becker K. Differential genomic and proteomic profiling of glioblastoma cells exposed to terpyridineplatinum(II) complexes. Free Radic Biol Med 46(8):1096-1108, 2009
  • Riedel A, End C, Christiansen H, Renner M, Bender C, Schmidt S, Korn B, Sueltmann H, Mollenhauer J. Construction of biosensor systems for determining the pathophysiological potential of carrageenan variants. Mol Biosyst 5(9):973-979, 2009
  • Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, Gdynia G, Ehemann V, Schnabel PA, Kuner R, Huber P, Schirmacher P, Breuhahn K. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 69(6):2234-2243, 2009
  • Buness A, Ruschhaupt M, Kuner R, Tresch A. Classification across gene expression microarray studies. BMC Bioinformatics 10:453, 2009
  • Fröhlich H, Sahin O, Arlt D, Bender C, Beissbarth T. Deterministic Effects Propagation Networks for reconstructing protein signaling networks from multiple interventions. BMC Bioinformatics 10:322, 2009
  • Fröhlich H, Tresch A, Beissbarth T. Nested effects models for learning signaling networks from perturbation data. Biom J 51(2):304-323, 2009
  • Kuner R, Hoffmann H, Sültmann H. [Gene expression profiling in lung cancer. Experimental research and clinical application]. Dtsch Med Wochenschr 134(11):519-521, 2009

2008

  • Fröhlich H, Fellmann M, Sültmann H, Poustka A, Beissbarth T. Predicting pathway membership via domain signatures. Bioinformatics 24(19):2137-2142, 2008
  • Fröhlich H, Fellmann M, Sültmann H, Poustka A, Beissbarth T. Estimating large-scale signaling networks through nested effect models with intervention effects from microarray data. Bioinformatics 24(22):2650-2656, 2008
  • Kuner R, Barth AS, Ruschhaupt M, Buness A, Zwermann L, Kreuzer E, Steinbeck G, Poustka A, Sültmann H, Nabauer M. Genomic analysis reveals poor separation of human cardiomyopathies of ischemic and nonischemic etiologies. Physiol Genomics 34(1):88-94, 2008
  • Korf U, Löbke C, Haller F, Sültmann H, Poustka A. Infrared-based protein detection arrays for quantitative proteomics. Expert Opin Drug Discov 3(2):273-283, 2008
  • Löbke C, Laible M, Rappl C, Ruschhaupt M, Sahin O, Arlt D, Wiemann S, Poustka A, Sültmann H, Korf U. Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling. Proteomics 8(8):1586-1594, 2008
  • Schlomm T, Näkel E, Lübke A, Buness A, Chun FK, Steuber T, Graefen M, Simon R, Sauter G, Poustka A, Huland H, Erbersdobler A, Sültmann H, Hellwinkel OJ. Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol 53(2):333-344, 2008
  • Schlomm T, Sültmann H, Köllermann J. [Identification and validation of clinically relevant molecular alterations in prostate cancer]. Urologe A 47(9):1193-1198, 2008
  • Haller F, Löbke C, Ruschhaupt M, Cameron S, Schulten HJ, Schwager S, von Heydebreck A, Gunawan B, Langer C, Ramadori G, Sültmann H, Poustka A, Korf U, Füzesi L. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). J Pathol 215(3):253-262, 2008
  • Haller F, Löbke C, Ruschhaupt M, Schulten HJ, Schwager S, Gunawan B, Armbrust T, Langer C, Ramadori G, Sültmann H, Poustka A, Korf U, Füzesi L. Increased KIT signalling with up-regulation of cyclin D correlates to accelerated proliferation and shorter disease-free survival in gastrointestinal stromal tumours (GISTs) with KIT exon 11 deletions. J Pathol 216(2):225-235, 2008
  • Sauermann M, Sahin O, Sültmann H, Hahne F, Blaszkiewicz S, Majety M, Zatloukal K, Füzesi L, Poustka A, Wiemann S, Arlt D. Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells. Oncogene 27(9):1320-1326, 2008
  • Boeuf S, Steck E, Pelttari K, Hennig T, Buness A, Benz K, Witte D, Sültmann H, Poustka A, Richter W. Subtractive gene expression profiling of articular cartilage and mesenchymal stem cells: serpins as cartilage-relevant differentiation markers. Osteoarthritis Cartilage 16(1):48-60, 2008
  • Eisenberger S, Ackermann K, Voggenreiter G, Sültmann H, Kasperk C, Pyerin W. Metastases and multiple myeloma generate distinct transcriptional footprints in osteocytes in vivo. J Pathol 214(5):617-626, 2008
  • Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Gröne HJ, Ganten TM, Sültmann H, Tüttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13(3):235-248, 2008
  • Hahne F, Mehrle A, Arlt D, Poustka A, Wiemann S, Beissbarth T. Extending pathways based on gene lists using InterPro domain signatures. BMC Bioinformatics 9:3, 2008

2007

  • Buness A, Kuner R, Ruschhaupt M, Poustka A, Sültmann H, Tresch A. Identification of aberrant chromosomal regions from gene expression microarray studies applied to human breast cancer. Bioinformatics 23(17):2273-2280, 2007
  • Froehlich H, Fellmann M, Sueltmann H, Poustka A, Beissbarth T. Large scale statistical inference of signaling pathways from RNAi and microarray data. BMC Bioinformatics 8:386, 2007
  • Fröhlich H, Fellmann M, Sültmann H, Poustka A, Beissbarth T. Estimating Large Scale Signaling Networks through Nested Effects Models from Intervention Effects in Microarray Data. Proc. German Conf. Bioinformatics (GCB):45 - 54, 2007
  • Loebke C, Sueltmann H, Schmidt C, Henjes F, Wiemann S, Poustka A, Korf U. Infrared-based protein detection arrays for quantitative proteomics. Proteomics 7(4):558-564, 2007
  • Sahin O, Löbke C, Korf U, Appelhans H, Sültmann H, Poustka A, Wiemann S, Arlt D. Combinatorial RNAi for quantitative protein network analysis. Proc Natl Acad Sci U S A 104(16):6579-6584, 2007
  • Schlomm T, Sültmann H, Poustka A, Sauter G, Hellwinkel OJ, Huland H. [Molecular high throughput research in prostate carcinoma]. Urologe A 46(9):1097-1100, 2007
  • Tresch A, Beissbarth T, Sültmann H, Kuner R, Poustka A, Buness A. Discrimination of direct and indirect interactions in a network of regulatory effects. J Comput Biol 14(9):1217-1228, 2007
  • Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sültmann H, Lyko F. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67(4):1419-1423, 2007
  • Geldyyev A, Koleganova N, Piecha G, Sueltmann H, Finis K, Ruschaupt M, Poustka A, Gross ML, Berger I. High expression level of bone degrading proteins as a possible inducer of osteolytic features in pigmented villonodular synovitis. Cancer Lett 255(2):275-283, 2007
  • Kuner R, Vogt M, Sultmann H, Buness A, Dymalla S, Bulkescher J, Fellmann M, Butz K, Poustka A, Hoppe-Seyler F. Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med (Berl) 85(11):1253-1262, 2007
  • Fröhlich H, Speer N, Poustka A, Beissbarth T. GOSim--an R-package for computation of information theoretic GO similarities between terms and gene products. BMC Bioinformatics 8:166, 2007
  • Seil I, Frei C, Sültmann H, Knauer SK, Engels K, Jäger E, Zatloukal K, Pfreundschuh M, Knuth A, Tseng-Chen Y, Jungbluth AA, Stauber RH, Jäger D. The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. Int J Cancer 120(12):2635-2642, 2007
  • Arlt D, Korf U, Beissbarth T, Sahin O, Löbke C, Fröhlich H, Kuner R, Sültmann H, Wiemann S, Poustka A. Analyse komplexer biologischer Netzwerke in der Krebs-Systembiologie. GenomXPress 02(02):4-6, 2007
  • Fröhlich H, Fellmann M, Kuner R, Poustka A, Sültmann H, Beissbarth T. Wie man aus Interventionseffekten über Signalwege in einer Zelle lernen kann. GenomXPressSonderausgabe NGFN:56-58, 2007
  • Kuner R, Ruschhaupt M, Buness A, Beissbarth T, Fröhlich H, Fellmann M, Poustka A, Sültmann H. DNA-Mikroarrays: Routine in der biomedizinischen Forschung. BIOspektrum (Sonderausgabe Biotechnica):16-17, 2007
  • Poustka A, Lichter P, Hoheisel J, Herrmann B, Argo S, Kuner R, Hahn M, Sültmann H. Tausende von Messungen in jedem einzelnen Experiment: Gensignaturen für das klinische Management und Verständnis menschlicher Erkrankungen. GenomXPress Sonderausgabe NGFN:37-39, 2007
  • Sültmann H, Kuner R. Gene expression signatures for disease diagnosis and prognosis. Science Inside 2 NGFN Abschlußbroschüre:56-57, 2007
  • Sültmann H, Kuner R, Beissbarth T. From gene signatures to molecular mechanisms of cancer. Science Inside 2 NGFN-Abschlußbroschüre:54-55, 2007
  • Sültmann H, Poustka A. Molekulare Diagnose des Mammakarzinoms: Gen-Signaturen zur besseren Therapieentscheidung bei Brustkrebs. BIOforum 2(2):34-35, 2007

2006

  • Barth AS, Kuner R, Buness A, Ruschhaupt M, Merk S, Zwermann L, Kääb S, Kreuzer E, Steinbeck G, Mansmann U, Poustka A, Nabauer M, Sültmann H. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol 48(8):1610-1617, 2006
  • Finis K, Sültmann H, Ruschhaupt M, Buness A, Helmchen B, Kuner R, Gross ML, Fink B, Schirmacher P, Poustka A, Berger I. Analysis of pigmented villonodular synovitis with genome-wide complementary DNA microarray and tissue array technology reveals insight into potential novel therapeutic approaches. Arthritis Rheum 54(3):1009-1019, 2006
  • Schneider J, Ruschhaupt M, Buness A, Asslaber M, Regitnig P, Zatloukal K, Schippinger W, Ploner F, Poustka A, Sültmann H. Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. Int J Cancer 119(12):2974-2979, 2006
  • Sültmann H, Poustka A. [Microarrays for the identification of molecular markers in the diagnosis and therapy of renal cell carcinomas]. Urologe A 45(3):297-298, 300-294, 2006

2005

  • Haller F, Gunawan B, von Heydebreck A, Schwager S, Schulten HJ, Wolf-Salgo J, Langer C, Ramadori G, Sültmann H, Füzesi L. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 11(18):6589-6597, 2005
  • Schlomm T, Luebke AM, Sültmann H, Hellwinkel OJ, Sauer U, Poustka A, David KA, Chun FK, Haese A, Graefen M, Erbersdobler A, Huland H. Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. Int J Oncol 27(3):713-720, 2005
  • Sültmann H, von Heydebreck A, Huber W, Kuner R, Buness A, Vogt M, Gunawan B, Vingron M, Füzesi L, Poustka A. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 11(2 Pt 1):646-655, 2005
  • Arlt D, Huber W, Liebel U, Schmidt C, Majety M, Sauermann M, Rosenfelder H, Bechtel S, Mehrle A, Bannasch D, Schupp I, Seiler M, Simpson JC, Hahne F, Moosmayer P, Ruschhaupt M, Guilleaume B, Wellenreuther R, Pepperkok R, Sültmann H, Poustka A, Wiemann S. Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle. Cancer Res 65(17):7733-7742, 2005
  • Buness A, Huber W, Steiner K, Sültmann H, Poustka A. arrayMagic: two-colour cDNA microarray quality control and preprocessing. Bioinformatics 21(4):554-556, 2005
  • Dahl E, Sadr-Nabavi A, Klopocki E, Betz B, Grube S, Kreutzfeld R, Himmelfarb M, An HX, Gelling S, Klaman I, Hinzmann B, Kristiansen G, Grützmann R, Kuner R, Petschke B, Rhiem K, Wiechen K, Sers C, Wiestler O, Schneider A, Höfler H, Nährig J, Dietel M, Schäfer R, Rosenthal A, Schmutzler R, Dürst M, Meindl A, Niederacher D. Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol 205(1):21-28, 2005
  • Sültmann H, Wellenreuther R, Wiemann S, Argo S, Poustka A. Hochdurchsatz gegen den Krebs: Gemeinsam geht’s besser! GenomXpress 1(05):9-11, 2005

2004

  • Haller F, Kulle B, Schwager S, Gunawan B, von Heydebreck A, Sültmann H, Füzesi L. Equivalence test in quantitative reverse transcription polymerase chain reaction: confirmation of reference genes suitable for normalization. Anal Biochem 335(1):1-9, 2004
  • Schneider J, Buness A, Huber W, Volz J, Kioschis P, Hafner M, Poustka A, Sültmann H. Systematic analysis of T7 RNA polymerase based in vitro linear RNA amplification for use in microarray experiments. BMC Genomics 5(1):29, 2004
  • Sültmann H, Poustka A. Recent advances in transcription profiling of human cancer. Curr Opin Mol Ther 6(6):593-599, 2004
  • Wellenreuther R, Sültmann H, Pepperkok R, Poustka A, Wiemann S. Integrierte "Functional Genomics" Pipeline im NGFN. BIOspektrum 2:192, 2004
  • Wiemann S, Arlt D, Huber W, Wellenreuther R, Schleeger S, Mehrle A, Bechtel S, Sauermann M, Korf U, Pepperkok R, Sültmann H, Poustka A. From ORFeome to biology: a functional genomics pipeline. Genome Res 14(10B):2136-2144, 2004

2003

  • Huber W, von Heydebreck A, Sueltmann H, Poustka A, Vingron M. Parameter estimation for the calibration and variance stabilization of microarray data. Stat Appl Genet Mol Biol 2:Article3, 2003

2002

  • Huber W, Boer JM, von Heydebreck A, Gunawan B, Vingron M, Füzesi L, Poustka A, Sültmann H. Transcription profiling of renal cell carcinoma. Verh Dtsch Ges Pathol 86:153-164, 2002
  • Huber W, von Heydebreck A, Sültmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 Suppl 1:S96-104, 2002

2001

  • Boer JM, Huber WK, Sültmann H, Wilmer F, von Heydebreck A, Haas S, Korn B, Gunawan B, Vente A, Füzesi L, Vingron M, Poustka A. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 11(11):1861-1870, 2001
  • Huber W, von Heydebreck A, Sültmann H, Poustka A, Vingron M. Data preprocessing and quality control for DNA array expression profiling experiments. In: Mabrouk NE, Lengauer T, Sankoff D, Eds, eds. Currents in Computational Molecular Biology: Les Publications CRM Montreal; 2001:181-182.
  • Sültmann H, Poustka A. Indikationsspezifische cDNA Chips für die Krebsdiagnose. GenomeXpress 01(4):15-17, 2001

to top
powered by webEdition CMS